Risk of Stroke in Chronic Heart Failure Patients Without Atrial Fibrillation: Analysis of the Controlled Rosuvastatin in Multinational Trial Heart Failure (CORONA) and the Gruppo Italiano per lo Studio della Sopravvivenza nell'Insufficienza Cardiaca-Heart Failure (GISSI-HF) Trials

Circulation. 2015 Apr 28;131(17):1486-94; discussion 1494. doi: 10.1161/CIRCULATIONAHA.114.013760. Epub 2015 Mar 25.

Abstract

Background: Our aim was to describe the incidence and predictors of stroke in patients who have heart failure without atrial fibrillation (AF).

Methods and results: We pooled 2 contemporary heart failure trials, the Controlled Rosuvastatin in Multinational Trial Heart Failure (CORONA) and the Gruppo Italiano per lo Studio della Sopravvivenza nell'Insufficienza cardiaca-Heart Failure trial (GISSI-HF). Of the 9585 total patients, 6054 did not have AF. Stroke occurred in 165 patients (4.7%) with AF and in 206 patients (3.4%) without AF (rates 16.8/1000 patient-years and 11.1/1000 patient-years, respectively). Using Cox proportional-hazards models, we identified the following independent predictors of stroke in patients without AF (ranked by χ(2) value): age (hazard ratio, 1.34; 95% confidence interval, 1.18-1.63 per 10 years), New York Heart Association class (1.60, 1.21-2.12 class III/IV versus II), diabetes mellitus treated with insulin (1.87, 1.22-2.88), body mass index (0.74, 0.60-0.91 per 5 kg/m(2) up to 30), and previous stroke (1.81, 1.19-2.74). N-terminal pro B-type natriuretic peptide (available in 2632 patients) was also an independent predictor of stroke (hazard ratio, 1.31; 1.11-1.57 per log unit) when added to this model. With the use of a risk score formulated from these predictors, we found that patients in the upper third of risk had a rate of stroke that approximated the risk in patients with AF.

Conclusions: A small number of demographic and clinical variables identified a subset of patients who have heart failure without AF at a high risk of stroke.

Keywords: atrial fibrillation; heart failure; risk factors; sinus rhythm; stroke; ventricular ejection fraction.

Publication types

  • Meta-Analysis
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Aged
  • Aged, 80 and over
  • Atrial Fibrillation / etiology
  • Benzimidazoles / therapeutic use
  • Biomarkers / blood
  • Biphenyl Compounds
  • Cardiovascular Agents / therapeutic use
  • Diabetes Mellitus, Type 1 / complications
  • Fatty Acids, Omega-3 / therapeutic use*
  • Female
  • Fluorobenzenes / therapeutic use*
  • Follow-Up Studies
  • Heart Failure / complications
  • Heart Failure / drug therapy*
  • Humans
  • Hydroxymethylglutaryl-CoA Reductase Inhibitors / therapeutic use*
  • Kaplan-Meier Estimate
  • Male
  • Middle Aged
  • Natriuretic Peptide, Brain / blood*
  • Peptide Fragments / blood*
  • Proportional Hazards Models
  • Pyrimidines / therapeutic use*
  • Randomized Controlled Trials as Topic
  • Risk Factors
  • Rosuvastatin Calcium
  • Stroke / epidemiology
  • Stroke / etiology*
  • Stroke / prevention & control
  • Stroke Volume
  • Sulfonamides / therapeutic use*
  • Tetrazoles / therapeutic use

Substances

  • Benzimidazoles
  • Biomarkers
  • Biphenyl Compounds
  • Cardiovascular Agents
  • Fatty Acids, Omega-3
  • Fluorobenzenes
  • Hydroxymethylglutaryl-CoA Reductase Inhibitors
  • Peptide Fragments
  • Pyrimidines
  • Sulfonamides
  • Tetrazoles
  • pro-brain natriuretic peptide (1-76)
  • Natriuretic Peptide, Brain
  • Rosuvastatin Calcium
  • candesartan